Tumor biology and oncology drug-discovery leader with more than 14 years of experience advancing cancer therapeutic programs across tumor-intrinsic biology, target discovery and validation, oncogenic signaling, cancer genomics-informed research, in vitro and in vivo oncology models, precision oncology, immuno-oncology, radiopharmaceuticals, biologics, small molecules, and gene-editing platforms. Proven record leading discovery and translational studies that define disease mechanisms, prioritize targets, support lead selection, and advance oncology programs toward IND and CTA readiness and First-in-Human planning. Experienced scientific leader with a track record of building and mentoring research teams, directing multidisciplinary oncology programs, managing CRO and academic collaborations, evaluating external opportunities, and communicating complex biology to senior leadership, KOLs, external partners, and regulatory-facing teams. Recognized for high-impact publications, including first-author work in Cancer Cell, co-authored work in Cell Chemical Biology, more than 10 peer-reviewed publications, more than 50 scientific presentations, over 1 million dollars in secured research and development funding, and co-inventorship on a radiopharmaceutical diagnostic and therapeutic patent.